Whilst demanding, laboratories must do their most effective to help keep an current listing of appropriate DBZDs of their MS affirmation assays and look at no matter if these DBZDs will likely be detected on their distinct immunoassay platforms.An extensive overview was carried out by using the EMCDDA/EDND database frequently monitored by our resea